Clinical Trial Update: Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of surufatinib and camrelizumab with AS as first-line therapy for advanced metastatic pancreatic cancer; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING